Ruxolitinib

Author: Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 13.09.2021

Dieser Artikel auf Deutsch

Definition
This section has been translated automatically.

Inhibitor of Janus kinase (tyrosine kinase) used for the treatment of primary myelofibrosis, polycythemia vera and post-polycythemia vera myelofibrosis. The molecular formula is: C17H18N6.

Pharmacodynamics (Effect)
This section has been translated automatically.

Inhibition of Janus kinases 1 and 2 (see Janus kinases).

Indication
This section has been translated automatically.

See above. Experimental is the use in Alopecia areata.

Undesirable effects
This section has been translated automatically.

Dizziness and headaches. Thrombocytopenia, leukopenia and haemorrhage have also been described in the Phase III studies. Further increase in infections, hypertension.

Preparations
This section has been translated automatically.

Jakafi®, Jakavi®

Literature
This section has been translated automatically.

  1. Falto-Aizpurua L et al (2014) Emerging treatments in alopecia. Expert Opin Emerg Drugs 19:545-556
  2. Mesa R et al.(2016) The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. doi: 10.1111/bjh.14382.
  3. Kettle JG et al.(2016) Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1. Expert Opin Ther Pat 7:1-17.
  4. Kettle JG et al.(2016) Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2. Expert Opin Ther Pat 4:1-17.
  5. Pieri L et al. (2014) Ruxolitinib-Induced Reversal of Alopecia Universalis in a Patient with Essential Thrombocythemia. Am J Hematol 2014 doi: 10.1002/ajh.23871.
  6. Xing L et al (2014) Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition. Nat Med 20:1043-1049

Authors

Last updated on: 13.09.2021